Navigation Links
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Date:7/29/2008

~ Initiates IDX184 Phase I Clinical Study and Advances HCV Protease Inhibitor and Non-Nucleoside Polymerase Inhibitor Clinical Candidates into

IND-Enabling Preclinical Studies ~

CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a first-in-man study of IDX184 under a United States investigational new drug (IND) application. IDX184 is a once-daily, oral nucleotide prodrug polymerase inhibitor for the treatment of chronic hepatitis C. Today, Idenix also announced that is has selected a lead clinical candidate (IDX375) from its HCV non-nucleoside polymerase inhibitor discovery program and has advanced IDX375 into IND-enabling pharmacokinetic and toxicology studies. Idenix has also advanced two protease inhibitor drug candidates (IDX136 and IDX316) into IND-enabling pharmacokinetic and toxicology studies.

"We are pleased with the progress we have made in our hepatitis C discovery program in the past few months," said Jean-Pierre Sommadossi, Ph.D., chief executive officer of Idenix. "With IDX184 entering human testing and clinical candidates undergoing late-stage preclinical testing from our HCV non-nucleoside and protease inhibitor programs, we are progressing toward our ultimate goal of developing a proprietary combination of direct-acting antivirals for the treatment of hepatitis C."

IDX184 Nucleotide Prodrug Polymerase Inhibitor

IDX184 is a once-daily, oral nucleotide prodrug candidate based on Idenix's proprietary liver-targeting technology that has demonstrated HCV
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
4. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
6. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
7. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
8. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
9. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
10. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
11. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has ... - Global Strategic Business Report" report to their ... for Medical Oxygen Systems in US$ Thousands by the ... & Regulators, and Oxygen Conserving Devices. The report provides ... , Japan , ...
(Date:4/17/2015)... 17, 2015   IBA Molecular, a global ... today that it has signed a definitive agreement to ... (IBAM NA), to Illinois Health and Science (IHS). Under IHS ... independent company headquartered in Dulles, Virginia ... of new product and footprint synergies. IBA Molecular is ...
(Date:4/17/2015)... TAIPEI , April 17, 2015 TWi ... fully-owned subsidiary, TWi Pharmaceuticals USA , ... in the United States.  It has been in close ... wholesalers and expects to have its own label specialty ... soon in the U.S. pharma market. According ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... and Safety of Combination Drug Therapies -, ... Life,Sciences, Inc. (Nasdaq: CALP ) today ... & Services (CDAS). These new services,will help ... therapies,and identify potentially harmful combinations before therapies ...
... WILMINGTON, Del., Nov. 30 AstraZeneca (NYSE:,AZN) announced ... in the,ZEST (ZACTIMA Efficacy Study versus Tarceva) study, ... investigational once-daily oral anti-cancer drug,vandetanib. Data from the ... a randomized, double-blind, multi-center Phase III study to,assess ...
Cached Medicine Technology:Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds 2AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer 2
(Date:4/17/2015)... WA (PRWEB) April 17, 2015 ERGO-Pedic ... cushions is introducing two new products to help a ... low back pain relief are the second most common ... our first product, designed specifically to help relieve sitting ... Comfort Cushion, and thousands of happy customers later, we ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Alcohol and ... Dependence (NCADD) notes that drinking and driving has been ... At the same time, the link between alcohol and ... domestic abuse and violence and sexual assault, and their ... to the NCADD, 5.3 million adults in America were ...
(Date:4/17/2015)... 2015 “We have seen healing, a lot ... and present,” said Chaplain Shawn Kafader of Friendship Village. ... they had anything to contribute have created beautiful pieces of ... new art therapy program that was launched to benefit residents ... from School of the Art Institute in Chicago, worked as ...
(Date:4/17/2015)... D.C. (PRWEB) April 17, 2015 In ... issued the following statement: “On Wednesday April 15th, the ... and adopted a resolution recognizing the Armenian Genocide, “paying ... memory of the one-and-a-half million innocent Armenian victims who ... Christians (IDC) extols the EU for this timely and ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
Breaking Medicine News(10 mins):Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
... which men are at increased risk, scientists say , MONDAY, ... identified key gene variants tied to an increased risk of ... step toward understanding which men are at high risk for ... not been any clear genetic risk factors that can account ...
... 1 Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, ... the companies have begun enrolling patients in an international ... patients with non-squamous non-small cell lung cancer (NSCLC) who ... , "Nexavar has proven efficacy in liver cancer and ...
... Two of the nation,s most rapidly growing retained physician search ... Inc., Atlanta, GA, have agreed to merge their operations under ... not disclosed. , , Crutchfield Capital Corporation served ... "Successful mergers are built upon cultural fit, the integrity of ...
... and response at national and local level , , ... $1 million over the next three years through the Ryder ... response efforts, making it the newest member of the American ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , ...
... on Rebuilding Revenue Base While Stabilizing Costs--, ... /PRNewswire-FirstCall/ - Vancouver, BC, Canada - Neovasc Inc. (TSXV: NVC), ... 31, 2009. , "The first quarter continued to show financial ... Neovasc on our most promising growth areas," said Alexei Marko, ...
... clinical recommendations encourage cardiologists to examine the mouth and periodontists ... June 1 Cardiovascular disease, the leading killer of men ... health issue contributing to 2,400 deaths each day. Periodontal disease, ... that support the teeth affects nearly 75 percent of Americans ...
Cached Medicine News:Health News:Researchers Spot Genes Linked to Testicular Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Unprecedented Merger Occurs in Retained Physician Search Industry 2Health News:Unprecedented Merger Occurs in Retained Physician Search Industry 3Health News:Ryder System, Inc. Joins the American Red Cross Annual Disaster Giving Program 2Health News:Ryder System, Inc. Joins the American Red Cross Annual Disaster Giving Program 3Health News:Ryder System, Inc. Joins the American Red Cross Annual Disaster Giving Program 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 2Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 3Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 5Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 6Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 7Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 8Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 9Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 10Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 11Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4
... biopsies of soft tissue. Lightweight and compact, ... control. Precise, rapid firing mechanism provides intact ... easy penetration into the specimen with less ... of cannula helps assure an intact tissue ...
... The Bard EXPRESS Seeding Cartridge System is ... delivering radioactive seeds and spacers into a ... Each cartridge has a(n): outer radiation safety ... synthetic absorbable spacers, integrally molded fitting that ...
... very easy to use Ambulatory Urodynamic recorder ... with practising urologists as an invaluable aid ... dysfunctions. The system offers the possibility to ... a natural bladder filling, extented over a ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
Medicine Products: